Table 1.
Baseline characteristics of patients in the developing and validation cohorts.
| Developing cohort | Validation cohort | P | |
|---|---|---|---|
| Total | 207 | 193 | |
| Age, ≤ 65/>65 (years) | 132/75 | 125/68 | 0.835 |
| Sex, male/female | 134/73 | 110/83 | 0.113 |
| Tumor location, head/neck/uncinate, body/tail, or multifocal | 122/75/10 | 109/79/5 | 0.365 |
| CA19-9, <37/≥37 U/mL | 58/149 | 45/148 | 0.282 |
| T stage, T1/2/3 | 59/122/26 | 56/119/18 | 0.582 |
| N stage, N0/1/2 | 60/99/41 | 61/96/43 | 0.456 |
| TNM stage, I/II/III | 51/112/44 | 57/90/46 | 0.319 |
| Grade, G1/2/3 | 22/122/63 | 12/113/68 | 0.224 |
| TSR, >1/≤ 1 | 120/87 | 112/81 | 0.849 |
| R status, R0/R1 | 136/71 | 120/73 | 0.463 |
| Postoperative adjuvant therapy, with/without | 199/8 | 187/6 | 0.681 |
| Median follow-up (months) | 14.2 | 12.4 | 0.105 |
CA19-9, carbohydrate antigen 19-9; TNM, tumor–node–metastasis; TSR, tumor–stroma ratio.